Company Encyclopedia
View More
name
BioKangtai
300601.SZ
Shenzhen Kangtai Biological Products Co., Ltd. researches and develops, produces, and sells various types of human vaccines in China. The company’s marketed vaccines include 13-valent pneumococcal polysaccharide conjugate vaccine, varicella vaccine, freeze-dried, hepatitis B vaccine, inflammatory vaccine, 23-valent pneumococcal polysaccharide vaccine, DTAP/HIB combined vaccine, diphtheria, tetanus and acellular pertussis combined vaccine, adsorbed, rabies vaccine (human diploid cell) for human use, hib conjugate vaccine, measles and rubella combined vaccine, sars-cov-2 vaccine, inactivated, and covid-19 vaccine. Its research and development vaccines comprise measles, mumps and rubella vaccine, 2DTAP- HIB-IPV, 4-valent influenza (split), poliomyelitis vaccine (vero cells), and inactivated, sabin strain.
1.585 T
300601.SZMarket value -Rank by Market Cap -/-

Financial Score

08/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking65/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE-1.04%D
    • Profit Margin-3.72%D
    • Gross Margin83.47%A
  • Growth ScoreD
    • Revenue YoY-11.03%E
    • Net Profit YoY-119.46%E
    • Total Assets YoY-2.63%D
    • Net Assets YoY-1.02%D
  • Cash ScoreE
    • Cash Flow Margin-2689.28%E
    • OCF YoY-11.03%E
  • Operating ScoreD
    • Turnover0.19D
  • Debt ScoreB
    • Gearing Ratio32.01%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    BioKangtai: Quadrivalent influenza virus split vaccine (for the population aged 6-35 months) has initiated Phase I clinical trials

    BioKangtai: Quadrivalent influenza virus split vaccine (6-35 months age group) has initiated Phase I clinical trial

    Zhitong·
    SZ
    300601
    -0.70%
    Zhitong·
    SZ
    300601
    -0.70%

    BioKangtai released its performance for the first three quarters, with a net profit attributable to the parent company of 49.1577 million yuan, a decrease of 86%

    BioKangtai released its third-quarter report for 2025, with operating revenue for the first three quarters amounting to 2.063 billion yuan, a year-on-year increase of 2.24%. The net profit attributable to the parent company was 49.1577 million yuan, a year-on-year decrease of 86%. The net profit after deducting non-recurring gains and losses was 27.8789 million yuan, a year-on-year decrease of 90.82%. The basic earnings per share were 0.04 yuan

    Zhitong·
    SZ
    300601
    -0.70%
    Zhitong·
    SZ
    300601
    -0.70%

    BioKangtai's net profit for the third quarter is 11.6 million yuan, and the net profit for nine months is 49.2 million yuan

    Zhitong·
    SZ
    300601
    -0.70%
    Zhitong·
    SZ
    300601
    -0.70%

    BioKangtai and AstraZeneca sign a license termination agreement

    BioKangtai and AstraZeneca signed a termination agreement to end the research, production, and commercialization cooperation of the ChAdOx1 adenovirus vector COVID-19 vaccine. Due to changes in the market environment and the impact of COVID-19 vaccine variants, both parties decided to terminate the original licensing agreement after friendly consultations, with all rights and obligations ending from the effective date of the new agreement

    Zhitong·
    SZ
    300601
    -0.70%
    Zhitong·
    SZ
    300601
    -0.70%

    BioKangtai: Application for marketing authorization of trivalent influenza virus split vaccine accepted

    According to the Zhitong Finance APP, BioKangtai announced that the company's application for marketing authorization of the influenza virus split vaccine has recently received the "Acceptance Notice" issued by the National Medical Products Administration. This marketing authorization application for the influenza virus split vaccine is applicable to individuals aged 3 years and older and can stimulate the body to produce immunity against the influenza virus, used for the prevention of influenza caused by vaccine-related strains of the influenza virus

    Zhitong·
    SZ
    300601
    -0.70%
    Zhitong·
    SZ
    300601
    -0.70%
    © 2025 Longbridge｜Disclaimer